Functional Neurological Disorder (FND) involves neurological symptoms arising from brain network changes rather than structural damage, often described as a “software” issue rather than a “hardware” problem. Symptoms…
Pompe disease is a progressive, life-threatening genetic neuromuscular disorder. Late-onset Pompe disease (LOPD), affecting individuals over one year old, leads to trunk and proximal muscle weakness, often impacting…
NEW YORK (Reuters Health) – A secondary analysis of a previous study provides functional data that further supports the benefits of alteplase therapy when given up to 4.5…
NEW YORK (Reuters Health) – Pain from cluster headaches is substantially relieved within half an hour after dosing with 5 to 10 mg of zolmitriptan nasal spray, according…
NEW YORK (Reuters Health) – Giving high-flow oxygen therapy for 15 minutes to emergency department patients with headaches provides rapid relief and reduces hospital stays, use of CT…
NEW YORK (Reuters Health) – Given together, nortriptyline and gabapentin are more effective than either agent alone in treating neuropathic pain, according to a report in the September…
NEW YORK (Reuters Health) – In young women, the presence of lupus anticoagulant is associated with a more than 40-fold increased risk of stroke and 5-fold increased risk…
NEW YORK (Reuters Health) – The results of a large population-based study in Denmark suggest that children born to women who use selective serotonin reuptake inhibitors (SSRIs) in…
NEW YORK (Reuters Health) – Increased brain amyloid load is associated with an increased risk of progression from mild cognitive impairment (MCI) to Alzheimer disease (AD), according to…
NEW YORK (Reuters Health) – Biomarkers of endothelial dysfunction are elevated in premenopausal women with migraine, which may help to explain the link between migraine and strokes, according…
NEW YORK (Reuters Health) – New guidelines issued jointly by the American Academy of Neurology and the Child Neurology Society point out that children with microcephaly are at…
